TAXIS Pharmaceuticals
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9 Deerpark Dr Ste M, Monmouth Junction, ...Phone Number
(732) 230-3074Website
www.taxispharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About TAXIS Pharmaceuticals
TAXIS Pharmaceuticals is a clinical-stage company focused on developing investigational therapies to combat antimicrobial resistance, addressing the root causes of the issue and targeting the foundation of bacterial survival. Their product pipeline includes TXA709, an oral anti-MRSA agent, Efflux Pump Inhibitors (EPIs) to enhance existing antibiotics, and Dihydrofolate Reductase Inhibitors (DHFRIs) aimed at treating highly resistant gonorrhea. The company aims to eliminate the threat of antimicrobial resistance across a wide range of infectious diseases, with a vision of a world where such resistance is a thing of the past. Their intended clients include healthcare providers and institutions dealing with infectious diseases and antimicrobial resistance.Explore more
TAXIS Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TAXIS Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when TAXIS Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at TAXIS Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if TAXIS Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if TAXIS Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once TAXIS Pharmaceuticals has new funding data
Earning: See what the market has to say on TAXIS Pharmaceuticals recently announced quarterly report
TAXIS Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if TAXIS Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at TAXIS Pharmaceuticals
Find more new buyers
Compare Similar Companies to TAXIS Pharmaceuticals
Compare insights from companies similar to TAXIS Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TAXIS Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TAXIS Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TAXIS Pharmaceuticals.
TAXIS Pharmaceuticals Tech Stack
A closer look at the technologies used by TAXIS Pharmaceuticals
TAXIS Pharmaceuticals News & Media
TAXIS Pharmaceuticals Announces Publication of Preclinical Data on Investigational Efflux Pump Inhibitor TXA11114 in journal Antibiotics
TXA11114 is an investigational indole carboxamide efflux pump inhibitor MIAMI, May 12, 2026 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuticals, a clinical-stage company developing investigational anti-resistance therapies to address antimicrobial resistance (AMR), today announced the publication...TAXIS Pharmaceuticals Names Angela Fonceca, PhD to Its Australian Board of Directors
TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, to its Board of Directors. MIAMI, Feb. 10, 2026 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, an industry professional with extensive biopharma experience, to its Board of...TAXIS Pharmaceuticals Earns FDA QIDP Designation for TXA14007, an Investigational Efflux Pump Inhibitor (EPI) to Combat Antibiotic-Resistant Pneumonia
TAXIS Pharmaceuticals has received an FDA QIDP designation for TXA14007, its investigational efflux pump inhibitor (EPI) in combination with levofloxacin for the treatment of hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP). MIAMI, July 15, 2025...TAXIS Pharmaceuticals Names Joe DePinto, MBA and Frank Carlo Pasqualone, MBA to Its Board of Directors
TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors. MIAMI, June 25, 2025 /PRNewswire-PRWeb/ -- TAXIS Pharmaceuticals, a clinical stage company at the forefront of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TAXIS Pharmaceuticals
Sign Up For FreeTo access detailed company insights
TAXIS Pharmaceuticals is a clinical-stage company focused on developing investigational therapies to combat antimicrobial resistance, addressing the root causes of the issue and targeting the foundation of bacterial survival. Their product pipeline includes TXA709, an oral anti-MRSA agent, Efflux Pump Inhibitors (EPIs) to enhance existing antibioti... Read More
